Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Danila on Considerations for Treatment Selection in Nonmetastatic CRPC

August 10th 2021

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

FDA Finalizes Guidance on MFS as End Point for Prostate Cancer Clinical Trials

August 10th 2021

The FDA has finalized guidance on the use of metastasis-free survival as an end point in clinical trials for nonmetastatic castration-resistant prostate cancer.

Dr. Danila on the Integration of Advanced Imaging in Prostate Cancer

August 9th 2021

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

Future Directions With PSMA Ligand–Directed Therapies

August 6th 2021

Highlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.

The VISION Study of 177Lu-PSMA-617 in mCRPC

August 6th 2021

Results of the phase 3 VISION study of 177Lu-PSMA PET in advanced prostate cancer are described.

CD38 Expression Linked With Poor OS in Prostate Cancer

August 3rd 2021

The role of CD38 within prostate cancer progression must be further explored, along with CD38-targeting in patients with high-risk disease.

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

August 2nd 2021

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Use of PSMA PET Scans in Advanced Prostate Cancer

July 30th 2021

Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.

Testing for PSMA in Community Settings

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.

Dr. Abida on the Clinical Significance of the TRITON2 Study in mCRPC

July 29th 2021

Wassim Abida, MD, PhD, discusses the clinical significance of the results from the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer.

Dr. Morris Discusses Ongoing Research With 177Lu-PSMA-617 in Prostate Cancer

July 28th 2021

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

Diagnostic and Therapeutic Applications of PSMA in Prostate Cancer

July 28th 2021

An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

July 27th 2021

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Genomic Prostate Score Could Impact Treatment Decisions in Diverse Prostate Cancer Populations

July 27th 2021

The net effect of the Oncotype DX Genomic Prostate Score in patients with favorable-risk prostate cancer was to move away from active surveillance, altering the understanding of how prognostic molecular assays that generate probabilities of poor outcome can impact treatment decisions in diverse populations.

Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPC

July 26th 2021

Christopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.

Genotypic and Phenotypic Biomarkers in Prostate Cancer

July 23rd 2021

A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.

Prostate Cancer Disease Complexity and Testing

July 23rd 2021

Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.

The VISION Study in Metastatic CRPC

July 23rd 2021

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

PSMA PET Imaging in Advanced Prostate Cancer

July 23rd 2021

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.